Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune-Related Rheumatological and Neurological Adverse Events Study
2024-516631-27-00Phase 2Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab, nivolumab, ipilimumab and relatlimab in cancer, sponsored by Amsterdam University Medical Center. Planned start Dec 2024; status: authorised.
02
Drugs
03
Conditions
cancer
Beyond the preview
Go deeper on 2024-516631-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516631-27-00.